Skip to main content
Epigral Limited logo

Epigral Limited — Investor Relations & Filings

Ticker · EPIGRAL ISIN · INE071N01016 LEI · 3358008YTT28JYLL4516 BSE.NS Manufacturing
Open in API
Filings indexed 551 across all filing types
Latest filing 2024-11-09 Investor Presentation
Country IN India
Listing BSE.NS EPIGRAL

About Epigral Limited

https://epigral.com/

Epigral Limited, formerly Meghmani Finechem Limited, operates an integrated chemical complex specializing in chlor-alkali and derivative products. The company’s core portfolio includes caustic soda, chlorine, and hydrogen, which serve as building blocks for its value-added downstream products. Key offerings include chloromethanes, hydrogen peroxide, and CPVC resin. Epigral is the first domestic producer of Epichlorohydrin (ECH), utilizing a bio-based manufacturing process. Its products are essential inputs for various applications in pharmaceuticals, textiles, water treatment, and plastics. The company focuses on expanding its specialty chemical portfolio through backward and forward integration, utilizing advanced technology to optimize production efficiency and meet the requirements of diverse global markets.

Recent filings

Filing Released Lang Actions
General Updates
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation – Q2FY25' and includes detailed financial highlights, operational updates, strategic plans, capex details, income statement, balance sheet, and a message from the Chairman and Managing Director. It references un-audited financial results for Q2 FY2025 and H1 FY2025, with extensive financial data and analysis. The document is explicitly described as an 'Investors Presentation' and is submitted pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The content matches the characteristics of an Investor Presentation, focusing on financials, strategy, and market position, rather than being a formal earnings release or annual/interim report. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support a high confidence level.
2024-11-09 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the un-audited financial results for the quarter ended September 30, 2024 (Q2 FY2025). It includes detailed financial highlights such as revenue, PAT, EBITDA, margins, and operational updates. The document also discusses capital expenditure and expansion plans, but the primary focus is on the quarterly financial performance. The document is explicitly titled as a "Press Release for Un-Audited Financial Results – Q2 FY2025" and references Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which typically governs disclosure of financial results. The content is consistent with an Earnings Release (ER) as it provides key financial highlights and operational updates for the quarter without the comprehensive detail of a full interim report. The document length (8090 characters) and content confirm it is not merely an announcement of a report but the actual earnings release. Therefore, the appropriate classification is Earnings Release (ER).
2024-11-09 English
Capacity addition
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It announces the Board of Directors' approval for expansion of production capacity, including details on capacity, investment, financing, and rationale. The document is short (2189 characters) and is an announcement of a corporate action rather than a detailed report or financial statement. It does not contain financial results, audit information, or management discussion. This fits the category of Capital/Financing Update (CAP), as it relates to capacity expansion and investment plans, which are financing-related updates disclosed to the market.
2024-11-09 English
Outcome of Board Meeting
Regulatory Filings
2024-11-09 English
Financial Result Updates
Regulatory Filings
2024-11-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is a notice from Epigral Limited informing the stock exchanges and investors about a revised schedule for a conference call to discuss the Q2FY25 financial results. It includes details about the date, time, participants, and dial-in numbers for the call. There are no actual financial statements or detailed financial analysis included in the text. The document is essentially an announcement of an upcoming earnings call, not the transcript or the earnings release itself. Therefore, it fits best under the category of Call Transcript (CT) as it relates to a conference call about earnings results, but since it is only an intimation of the call and not the transcript, the closest appropriate classification is Call Transcript (CT) because the document is specifically about the conference call for earnings discussion, which is the typical use of CT category for such notices.
2024-11-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.